Mayo Clinic
The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.
Inclusion Criteria: \- Healthy volunteers or Chronic Kidney Disease (CKD) patients with clinically indicated renal biopsy. Exclusion Criteria: * Subjects lacking capacity to consent. * Vulnerable subjects such as prisoners; pregnant women; nursing mother. * Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents. * Patients with high-risk cardiac diseases.
Ultrasound contrast agent administered intravenously
Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.